Hepion Pharmaceuticals 2025 10-K: $0 Revenue, $(0.88) EPS on $(8.28) M Net Loss
I'm LongbridgeAI, I can summarize articles.Hepion Pharmaceuticals reported no revenue for 2025, with a net loss of $(8.28) million or $(0.88) per share, despite narrowing its operating loss to $(4.16) million from $(19.35) million in 2024. The company is shifting focus to CE-marked diagnostics for commercialization in non-U.S. markets after winding down its ASCEND-NASH trial due to funding issues. Cost reductions in R&D and administrative expenses contributed to lower losses. The strategic pivot aims to enhance market readiness in the EU with new diagnostic products.
Hepion Pharmaceuticals reported zero commercial product revenue for the years ended December 31, 2025 and 2024 and posted a net loss of $(8.28) million in 2025, or $(0.88) per share, driven by continued development and restructuring activities. The company narrowed its operating loss to $(4.16) million in 2025 from $(19.35) million in 2024, reflecting reduced R&D and general and administrative expenses following program wind-downs and cost reductions. Hepion repositioned its business in 2025 with a strategic move into CE-marked diagnostics to enable near-term commercialization in eligible non-U.S. markets.
Financial Highlights
- Revenues: $0 — no commercial product revenue for the years ended December 31, 2025 and 2024.
- Operating Income (Loss): Loss from operations of $(4.16) million (2025) versus $(19.35) million (2024); operating loss decreased due to lower R&D and G&A expenses.
- Net Income (Net loss): Net loss of $(8.28) million for 2025 versus $(13.19) million for 2024.
- Net Income Per Share: Net loss per common share — basic and diluted: $(0.88) (2025) versus $(107.35) (2024).
Business Highlights
- Clinical program adjustments: The ASCEND-NASH trial was wound down in 2024 and closed in August 2024 due to a funding shortfall, a decision taken to preserve patient safety.
- Strategic pivot to diagnostics: In May 2025, Hepion licensed CE-marked tests covering celiac, respiratory multiplex, H. pylori, and hepatocellular carcinoma diagnostics to enter EU and other eligible markets.
- Commercial readiness in EU: Acquisition of CE-marked diagnostics provides near-term go-to-market capability outside the U.S., supporting a strategic shift from clinical therapeutics toward diagnostic products.
- Operational cost reductions: Headcount reductions and cuts to R&D in 2025 materially lowered clinical and G&A spending versus 2024, conserving cash and reducing operating losses.
Original SEC Filing: Hepion Pharmaceuticals, Inc. [ HEPA ] - 10-K - Mar. 11, 2026